Merck Receives FDA “Complete Response” On Gardasil For Women 27-45
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also receives complete response to its sBLA for cross-protection.
You may also be interested in...
Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.